Robeco Institutional Asset Management B.V. Trims Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Robeco Institutional Asset Management B.V. cut its holdings in DexCom, Inc. (NASDAQ:DXCM) by 97.8% during the third quarter, Holdings Channel reports. The institutional investor owned 23,060 shares of the medical device company’s stock after selling 1,003,493 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in DexCom were worth $1,546,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Van ECK Associates Corp grew its position in shares of DexCom by 14.0% in the 3rd quarter. Van ECK Associates Corp now owns 20,191 shares of the medical device company’s stock worth $1,463,000 after buying an additional 2,475 shares during the period. Empire Life Investments Inc. purchased a new stake in shares of DexCom in the 3rd quarter worth about $5,613,000. Arcadia Investment Management Corp MI grew its position in shares of DexCom by 1,111.0% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 19,800 shares of the medical device company’s stock worth $1,327,000 after buying an additional 18,165 shares during the period. Clear Creek Financial Management LLC grew its position in shares of DexCom by 175.1% in the 3rd quarter. Clear Creek Financial Management LLC now owns 8,146 shares of the medical device company’s stock worth $546,000 after buying an additional 5,185 shares during the period. Finally, Symmetry Partners LLC purchased a new stake in shares of DexCom in the 3rd quarter worth about $990,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other DexCom news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DXCM. Raymond James reduced their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Canaccord Genuity Group reissued a “buy” rating and set a $145.00 price objective on shares of DexCom in a research report on Tuesday, July 23rd. Barclays cut their price objective on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research report on Monday, July 29th. Robert W. Baird increased their price objective on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, August 5th. Finally, Stifel Nicolaus increased their price objective on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $69.96 on Friday. The firm’s 50 day moving average price is $69.66 and its 200-day moving average price is $93.70. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The stock has a market capitalization of $27.33 billion, a PE ratio of 41.89, a price-to-earnings-growth ratio of 2.10 and a beta of 1.17.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.